The Impact of Fracture Incidence on Health Related Quality of Life among Community-Based Postmenopausal Women

Table 1

Baseline (first assessment) characteristics of the study women.

	Number	Incident fracture during the follow-up		value
		No ( = 2,606)	Yes ( = 266)
Age (years), mean (standard deviation (sd))	2,872	66.8 (8.8)	67.3 (9.2)	0.36
Body mass index (kg/m^2), mean (sd)	2,615	25.9 (5.3)	26.0 (5.1)	0.77
Private health insurance, (%)	2,843	2,480 (96.1)	251 (95.8)	0.82
Tertiary education, (%)	2,827	1,202 (46.8)	126 (49.0)	0.49
Prior year weight loss (≥5 kgs), (%)	2,839	169 (6.6)	17 (6.5)	0.99
Current smoking, (%)	2,855	117 (4.5)	21 (7.9)	0.01
Alcohol drinking (≥7 drinks/week), (%)	2,858	884 (34.1)	95 (36.1)	0.50
Prior fracture after 45 years, (%)	2,834	604 (23.5)	97 (37.5)	<0.001
Prior fracture after 45 years and being on treatment, (%)	2,807	259 (10.0)	46 (18.1)	<0.001
Any comorbidity, (%)	2,808	1,548 (60.7)	179 (69.9)	0.004
Number of falls in the prior year, (%)	2,852			0.04
0		1,633 (63.1)	148 (56.1)
1		631 (24.4)	71 (26.9)
2		324 (12.5)	45 (17.1)

Prior fracture after the age of 45 years and being on treatment for osteoporosis at baseline (first assessment). Treatment was defined as self-reported use of antiosteoporosis medications (i.e., oestrogen, selective oestrogen receptor modulators, bisphosphonates, calcitonin, parathyroid hormone, and strontium).
Ever diagnosed with asthma, chronic bronchitis/emphysema, osteoarthritis/degenerative joint disease, rheumatoid arthritis, high cholesterol, hypertension, or osteoporosis.